Mecamylamine Articles
AGI's CID drug shows benefit at higher dose
23 March 2009
AGI's loss deepens on flat revenue
22 September 2008
AGI begins dosing in Ph II CID trial
11 February 2008
Targacept to advance drug into clinicals
29 October 2007
R&D costs double AGI's 1st-half loss
24 September 2007
Targacept announces positive mecamylamine HCl data
30 July 2007
CoMentis starts Ph II AMD study
16 April 2007
AGI reports good initial results from two Ph II trials
5 February 2007
Targacept's TRIDMAC improves on Celexa
20 November 2006
Anti-alcohol consumption patch in development
26 April 2004
Mecamylamine promising in Tourette syndrome
13 July 2000
Elan's Combi Nicotine Patch A Partial Success
24 November 1998
Elan Acquires Sano In Deal Valued At $375 Million
17 December 1997
Sano Anxiety Patch Enters Ph III
3 March 1997
Showing 1-15 of 15 articles
- 1
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
